



Biosignal Limited

Suite 145, Level 1
National Innovation Centre
Australian Technology Park
EVELEIGH NSW 1430

Telephone +61 2 9209 4126
Facsimile +61 2 9209 4306

ACN 071 781 363
ABN 45 071 781 363

ASX Announcement

Biosignal raises \$257,500 from Share Purchase Plan

24 September 2008, Sydney: Biosignal Limited (ASX: BOS) has, with support from 65 shareholders, raised \$257,500 through its recent Share Purchase Plan. 7,357,122 new shares will be allotted and issued this week.

Enquiries: Robert Vickery
(02) 9209-4305

r.vickery@biosignal.com.au

Rudi Michelson
Monsoon Communications
0411 402 737

rudim@monsoon.com.au

About Biosignal and the anti-biofilm technology

Biosignal is commercialising a distinctive anti-bacterial technology. This technology is proving highly effective across applications ranging from industrial to medical products. Biosignal's anti-biofilm technology is based on a discovery that the eastern Australian seaweed *Delisea pulchra* produces natural furanones that disable bacteria's ability to colonise surfaces. The fundamental problem with existing anti-bacterials, including antibiotics, is bacterial resistance. Bacteria rapidly produce resistant strains when faced with strong selective pressure by biocides. Furanones lull bacteria to inaction and appear to avoid the problem of bacterial resistance.